Journal article

AN EFFECTIVE AGE-UNRESTRICTED M-AMSA-BASED 2ND-LINE REGIMEN FOR POOR-PROGNOSIS ACUTE MYELOID-LEUKEMIA

AM WATSON, J SEYMOUR, N LEE, M WHITESIDE, F FIRKIN

EUROPEAN JOURNAL OF HAEMATOLOGY | WILEY | Published : 1994

Abstract

The efficacy and toxicity of a regimen consisting of amsacrine (m-AMSA), cytarabine, and thioguanine for remission-induction therapy in poor prognosis categories of acute myeloid leukaemia (AML) were determined in a single arm study of 46 patients. The study group consisted of 17 patients with disease refractory to daunorubicin plus cytarabine-based induction regimens, 22 patients with disease which had relapsed during daunorubicin plus cytarabine maintenance therapy, or following completion of this maintenance programme after receiving > or = 500 mg daunorubicin/m2, and 7 previously untreated patients where cardiac disease contraindicated anthracycline therapy. Complete remission (CR) was a..

View full abstract